9 results about "Neisseria" patented technology

Disclosed herein are novel methods and compositions for rapidly extracting and amplifying nucleic acids from a sample where the sample is combined with an extraction reagent comprising a reducing agent to form a mixture and incubating said mixture at ambient temperature for a period of time not exceeding 30 minutes to generate a nucleic acid extract. In certain embodiments of the method, the nucleic acid extract is subjected to a nucleic acid amplification reaction. In certain aspects, oligonucleotide primers specific for nucleic acids of Chlamydia species and / or Neisseria species are added prior to initiating the amplification reaction.

The invention belongs to the technical field of biological medicines, and particularly relates to a neisseria gonorrhoeae chromogenic culture medium. According to the chromogenic culture medium, a supplement and a composite bacteriostatic agent are additionally added into a gonococcus culture medium, and the supplement is prepared from 50-200 ml / L of horse serum, 1-20 mg / L of hemin chloride, 25-250 mg / L of L-proline beta-naphthylamide hydrochloride, 500-5000 mg / L of 1, 3, 4-trimethyl-1, 3-pentanediol monoisobutyrate, 10-20 mg / L of sodium chloride, 10-20 mg / L of sodium chloride, 10-20 mg / L of sodium chloride, 10-20 mg / L of sodium chloride and 10-20 mg / L of sodium chloride. The invention relates to a neisseria gonorrhoeae culture medium, which is characterized in that neisseria gonorrhoeae in a sample can be directly separated and identified by adopting the culture medium, and a separated bacterial colony can be directly used for a drug sensitive test. The neisseria gonorrhoeae can be directly separated and identified by adopting the neisseria gonorrhoeae culture medium for the drug sensitive test of neisseria gonorrhoeae in the sample.

This invention relates generally to polynucleotides, polypeptides, compositions, methods and uses for eliciting an immune response to Neisseria, methods for immunizing a subject against a Neisseria infection, and methods for preventing and / or treating a Neisseria infection in a subject. More particularly, the invention relates to antigenic Neisseria polypeptides and encoding polynucleotides, and related uses and methods, including use for preparing compositions and medicaments for eliciting an immune response to Neisseria, for immunizing a subject against a Neisseria infection, and for preventing and / or treating a Neisseria infection in a subject. The invention also relates to methods for producing therapeutic anti-Neisseria antigen-binding molecules, and therapeutic uses of those antigen-binding molecules.

Isolated antigen binding polypeptides having a heavy chain variable region and / or light chain variable region that specifically binds to a lipo-oligosaccharide (LOS) epitope of Neisseria gonorrhoeae as well as antibodies and antigen binding antibody fragments containing the heavy chain variable region and / or the light chain variable region that bind to a lipo-oligosaccharide (LOS) epitope of Neisseria gonorrhoeae are provided. Pharmaceutical compositions and kits comprising the isolated antigen binding polypeptide and antibodies or antigen binding antibody fragments thereof comprising the antigen binding polypeptide are also provided, along with methods of treating an infection caused by Neisseria gonorrhoeae and methods of making the polypeptides, antibodies and antigen-binding antibody fragments.

Provided are a method for enhancing the immunogenicity of a recombinant protein antigen and use thereof. The method comprises conjugating a polysaccharide with a recombinant protein antigen to form a nano-scale protein antigen. The polysaccharide is selected from sodium hyaluronate, chitosan, glucan, fucoidan, and sodium alginate. The recombinant protein antigen is a protein antigen derived from a bacterium. The bacterium belongs to the genus of Staphylococcus, Neisseria, Klebsiella, Escherichia, Clostridium, Salmonella, Shigella, Pseudomonas, Acinetobacter, Bordetella, Enterococcus, Haemophilus, Mycobacterium, or Streptococcus. The method not only improves the immunogenicity of the recombinant protein antigen, but also overcomes the defects of competitive immunoregulation and poor immune enhancement effects caused by bacterial capsular polysaccharide modification. The method also has the advantages of high clinical application value, simple starting material acquisition, low cost, good process stability, ease in scale expansion, high safety, and the like.

Self-adjuvanting vaccine compositions comprising at least one modified immunogen via in vitro glycosylation methods that provide a rational approach for generating glycosylated versions of immunogens via the reducing end of a linear carbohydrate, the reducing end containing an N-acyl-2-amino moiety. Self-adjuvanting vaccine compositions comprising a plurality of heterologous immunogens associated with a multivalent carrier, wherein at least one immunogen is glycosylated to allow for mucosal delivery. Self-adjuvanting vaccine compositions comprising multivalent carriers and related methods using the self-adjuvanting vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection. Pathogens for which this approach may be useful include, but are not limited to, influenza viruses, rhinoviruses, human immunodeficiency viruses (HIV), respiratory syncytial virus (RSV), coronaviruses, Babesia, Borrelia, Neisseria, and Chlamydia, and the related diseases thereof.